Krystal Biotech announced on Friday that Vyjuvek had been approved by the FDA to treat a rare skin disorder. The company said it plans to launch the gene therapy by the third quarter. Krystal also ...
Shares of Krystal Biotech (NASDAQ: KRYS) were up more than 15% Monday morning. The company announced on Friday that it had received Food and Drug Administration (FDA) approval for Vyjuvek (beremagene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results